Should we target patients with autoimmune diseases for human papillomavirus vaccine uptake?

Expert Rev Vaccines. 2014 Aug;13(8):931-4. doi: 10.1586/14760584.2014.930346. Epub 2014 Jun 17.

Abstract

Human papillomavirus (HPV) is the cause of most cases of cervical cancer worldwide. Studies suggest that patients with autoimmune diseases (AD) may be at increased risk for persistent HPV infection, cervical dysplasia, and possibly, cervical cancer. Despite this heightened risk, and studies demonstrating the safety and efficacy of the HPV vaccine in this population, uptake among patients with AD, and in the overall population, remains low. A number of studies suggest that this may be attributed to lack of patient and provider awareness, no school-based requirement for vaccination, and a hesitancy to discuss sexually transmitted diseases with adolescents. Among patients with AD, access to preventive care in general may be reduced. Overall, heightened public health efforts are needed to improve HPV vaccination uptake in the entire population and among patients with AD who may be at increased risk for persistent infection and for cervical dysplasia.

Keywords: autoimmune disease; cervical dysplasia; human papillomavirus vaccine; rheumatoid arthritis; systemic lupus erythematosus.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Autoimmune Diseases / complications*
  • Female
  • Health Knowledge, Attitudes, Practice
  • Humans
  • Papillomavirus Infections / epidemiology*
  • Papillomavirus Infections / prevention & control*
  • Papillomavirus Vaccines / administration & dosage*
  • Patient Acceptance of Health Care
  • Vaccination / statistics & numerical data*

Substances

  • Papillomavirus Vaccines